The vascular disrupting agent ZD6126 shows increased antitumor efficacy and enhanced radiation response in large, advanced tumors

International Journal of Radiation Oncology Biology Physics

Volumn 62, Issue 3, 2005, Pages 846-853

  Siemann, Dietmar W ^a   Rojiani, Amyn M ^b  

^a UNIVERSITY OF FLORIDA   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Advanced disease; Radiation therapy; Vascular targeting

Indexed keywords

BIOLOGICAL RADIATION EFFECTS; BLOOD; CELLS; DISEASES; MORPHOLOGY;

CYTOSKELETON; ENDOTHELIAL CELLS; NEOPLASTIC DISEASES; XENOGRAFTS;

TUMORS;

N ACETYLCOLCHINOL PHOSPHATE;

ADVANCED CANCER; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CANCER RADIOTHERAPY; CARCINOMA CELL; CELL KILLING; CELL SURVIVAL; CLONOGENIC ASSAY; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; DRUG EFFICACY; FIBROSARCOMA; HISTOPATHOLOGY; HUMAN; HUMAN CELL; KAPOSI SARCOMA; KIDNEY CARCINOMA; LIMB TUMOR; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE; RADIATION RESPONSE; RODENT; SARCOMA CELL; SINGLE DRUG DOSE; SQUAMOUS CELL CARCINOMA; TUMOR NECROSIS; TUMOR VASCULARIZATION; TUMOR VOLUME; TUMOR XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANIMALS; BENZIMIDAZOLES; DRUG SCREENING ASSAYS, ANTITUMOR; FLUORESCENT DYES; HUMANS; MICE; MICE, INBRED C3H; MICE, NUDE; NECROSIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; ORGANOPHOSPHORUS COMPOUNDS; SARCOMA; TRANSPLANTATION, HETEROLOGOUS;

EID: 20344394640     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2005.02.048     Document Type: Article

References (55)

1. D. Ausprunk, J. Folkman Migration and proliferation of endothelial cells in preformed and newly formed blood vessels during tumor angiogenesis Microvasc Res 14 1977 53 65
2. J. Folkman How is blood vessel growth regulated in normal and neoplastic tissue? Cancer Res 46 1986 467 473
3. P. Hahnfeldt, D. Panigrahy, J. Folkman Tumor development under angiogenic signaling A dynamical theory of tumor growth, treatment response, and postvascular dormancy Cancer Res 59 1999 4770 4775
4. M.A. Konerding, A.J. Miodonski, A. Lametschwandtner Microvascular corrosion casting in the study of tumor vascularity A review Scanning Microsc 9 1995 1233 1244
5. B.A. Warren The vascular morphology of tumors H.I. Petersen Tumor blood circulation 1979 CRC Press Boca Raton, FL 1 47
6. P. Vaupel, F. Kallinowski, P. Okunieff Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors A review Cancer Res 49 1989 6449 6465
7. P. Vaupel, F. Kallinowski, P. Okunieff Blood flow, oxygen consumption and tissue oxygenation of human tumors Adv Exp Med Biol 277 1990 895 905
8. 2 tension measurements Cancer Res 51 1991 3316 3322
9. 2 predicts survival in advanced cancer of the uterine cervix Radiother Oncol 26 1993 45 50
10. M. Nordsmark, M. Overgaard, J. Overgaard Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck Radiother Oncol 41 1996 31 39
11. D.M. Brizel, R.K. Dodge, R.W. Clough Oxygenation of head and neck cancer Changes during radiotherapy and impact on treatment outcome Radiother Oncol 53 1999 113 117
12. J.M. Brown, A.J. Giaccia The unique physiology of solid tumors Opportunities (and problems) for cancer therapy Cancer Res 58 1998 1408 1416
13. M.R. Horsman, J. Overgaard The oxygen effect and the tumour microenvironment G.G. Steel Basic clinical radiobiology for radiation oncologists 2002 Edward Arnold London 158 168
14. J. Folkman, Y. Shing Angiogenesis J Biol Chem 267 1992 10931 10934
15. P.E. Thorpe Vascular targeting agents as cancer therapeutics Clin Cancer Res 10 2004 415 427
16. L.M. Ellis, W. Liu, S.A. Ahmad Overview of angiogenesis Biologic implications for antiangiogenic therapy Semin Oncol 28 2001 94 104
17. H.J. Bloemendal, T. Logtenberg, E.E. Voest New strategies in anti-vascular cancer therapy Eur J Clin Invest 29 1999 802 809
18. D.W. Siemann, D.J. Chaplin, M.R. Horsman Vascular-targeting therapies for treatment of malignant disease Cancer 100 2004 2491 2499
19. G.G. Steel, M.J. Peckham Exploitable mechanisms in combined radiotherapy-chemotherapy The concept of additivity Int J Radiat Oncol Biol Phys 5 1979 85 91
20. G.G. Dark, S.A. Hill, V.E. Prise Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature Cancer Res 57 1997 1829 1834
21. C.J. Lash, A.E. Li, M. Rutland Enhancement of the anti-tumour effects of the antivascular agent 5,6- dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs Br J Cancer 78 1998 439 445
22. L. Li, A. Rojiani, D.W. Siemann Targeting the tumor vasculature with combretastatin A-4 disodium phosphate Effects on radiation therapy Int J Radiat Oncol Biol Phys 42 1998 899 903
23. K. Grosios, S.E. Holwell, A.T. McGown In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug Br J Cancer 81 1999 1318 1327
24. A.M. Rojiani, L. Li, L. Rise Activity of the vascular targeting agent combretastatin A-4 disodium phosphate in a xenograft model of AIDS-associated Kaposi's sarcoma Acta Oncologica 41 2002 98 105
25. D.W. Siemann, A.M. Rojiani Enhancement of radiation therapy by the novel vascular targeting agent ZD6126 Int J Radiat Oncol Biol Phys 53 2002 164 171
26. D.W. Siemann, A.M. Rojiani Antitumor efficacy of conventional anticancer drugs is enhanced by the vascular targeting agent ZD6126 Int J Radiat Oncol Biol Phys 54 2002 1512 1517
27. D.J. Chaplin, S.A. Hill The development of combretastatin A4 phosphate as a vascular targeting agent Int J Radiat Oncol Biol Phys 54 2002 1491 1496
28. D.C. Blakey, F.R. Westwood, M. Walker Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models Clin Cancer Res 8 2002 1974 1983
29. D.W. Siemann Vascular targeting agents Horizons in Cancer Therapeutics 3 2002 4 15
30. W.R. Wilson, A.E. Li, D.S. Cowan Enhancement of tumor radiation response by the antivascular agent 5,6- dimethylxanthenone-4-acetic acid Int J Radiat Oncol Biol Phys 42 1998 905 908
31. D.W. Siemann, M.R. Horsman Targeting the tumor vasculature A strategy to improve radiation therapy Expert Rev Anticancer Ther 4 2004 321 327
32. H.M. Sandler, W.J. Curran Jr, A.T. Turrisi III The influence of tumor size and pre-treatment staging on outcome following radiation therapy alone for stage I non-small cell lung cancer Int J Radiat Oncol Biol Phys 19 1990 9 13
33. C. Nervi, G. Arcangeli, G. Badaracco The relevance of tumor size and cell kinetics as predictors of radiation response in head and neck cancer. A randomized study on the effect of intraarterial chemotherapy followed by radiotherapy Cancer 41 1978 900 906
34. V.T. DeVita, S. Hellman, S. Rosenberg Cancer Principles and practice of oncology 1997 Lippincott-Raven Philadelphia 268 273
35. W. Landuyt, B. Ahmed, S. Nuyts In vivo antitumor effect of vascular targeting combined with either ionizing radiation or anti-angiogenesis treatment Int J Radiat Oncol Biol Phys 49 2001 443 450
36. K.A. Smith, S.A. Hill, A.C. Begg Validation of the fluorescent dye Hoechst 33342 as a vascular space marker in tumours Br J Cancer 57 1988 247 253
37. A.C.S. Curtis Area and volume measurements by random sampling methods Med Biol Illustra 10 1960 261 266
38. M.J. Allalunis-Turner, D.W. Siemann Recovery of cell subpopulations from human tumour xenografts following dissociation with different enzymes Br J Cancer 54 1986 615 622
39. D.W. Siemann, I.M. Johansen, M.R. Horsman Radiobiological hypoxia in the KHT sarcoma Predictions using the Eppendorf histograph Int J Radiat Oncol Biol Phys 40 1998 1171 1176
40. G. Micheletti, M. Poli, P. Borsotti Vascular-targeting activity of ZD6126, a novel tubulin-binding agent Cancer Res 63 2003 1534 1537
41. P.D. Davis, G.J. Dougherty, D.C. Blakey ZD6126 A novel vascular-targeting agent that causes selective destruction of tumor vasculature Cancer Res 62 2002 7247 7253
42. H. Goto, S. Yano, H. Zhang Activity of a new vascular targeting agent, ZD6126, in pulmonary metastases by human lung adenocarcinoma in nude mice Cancer Res 62 2002 3711 3715
43. M.R. Horsman, R. Murata Vascular targeting effects of ZD6126 in a C3H mouse mammary carcinoma and the enhancement of radiation response Int J Radiat Oncol Biol Phys 57 2003 1047 1055
44. R.K. Jain Transport of molecules in the tumor interstitium A review Cancer Res 47 1987 3039 3051
45. R.F. Kallman, G.L. DeNardo, M.J. Stasch Blood flow in irradiated mouse sarcoma as determined by the clearance of Xenon-133 Cancer Res 32 1972 483 490
46. M.G. Pallavicini, M.E. Lalande, R.G. Miller Cell cycle distribution of chronically hypoxic cells and determination of the clonogenic potential of cells accumulated in G2 and M phases after irradiation of a solid tumor in vivo Cancer Res 39 1979 1891 1897
47. D.W. Siemann, K. Kochanski Combinations of radiation and misonidazole in a murine lung tumor model Radiat Res 86 1981 387 397
48. R.P. Hill An appraisal of in vivo assays of excised tumours Br J Cancer Suppl 41 1980 230 239
49. R.E. Durand Keynote address The influence of microenvironmental factors on the activity of radiation and drugs Int J Radiat Oncol Biol Phys 20 1991 253 258
50. I. Nishiguchi, V. Willingham, L. Milas Tumor necrosis factor as an adjunct to fractionated radiotherapy in the treatment of murine tumors Int J Radiat Oncol Biol Phys 18 1990 555 558
51. D.J. Chaplin, G.R. Pettit, S.A. Hill Anti-vascular approaches to solid tumour therapy Evaluation of combretastatin A4 phosphate Anticancer Res 19 1999 189 195
52. Y.S. Lew, A. Kolozsvary, S.L. Brown Synergistic interaction with arsenic trioxide and fractionated radiation in locally advanced murine tumor Cancer Res 62 2002 4202 4205
53. R. Murata, D.W. Siemann, J. Overgaard Interaction between combretastatin A4 disodium phosphate and radiation in murine tumours Radiother Oncol 60 2001 155 161
54. R. Murata, D.W. Siemann, J. Overgaard Improved tumor response by combining radiation and the vascular damaging drug 5,6-dimethylxanthenone-4- acetic acid Radiat Res 156 2001 503 509
55. M.R. Horsman, R. Murata, J. Overgaard Combination studies with combretastatin and radiation Effects in early and late responding normal tissues Radiother Oncol 64 2002 S50